Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another Class I AED recall

This article was originally published in The Gray Sheet

Executive Summary

Welch Allyn's Aug. 24 recall of AED 20 automatic external defibrillators is Class I, the most serious designation, FDA says. Some 1,722 devices manufactured between October 2003 and January 2005 at a facility in Buffalo Grove, Ill., display an error message from an "intermittent electrical connection" that could lead to device failure, the firm says. The action follows a string of recalls from Welch Allyn, including Class I recalls for the AED 20 in June 2006 and May 2005 (1"The Gray Sheet" June 19, 2006, In Brief)

You may also be interested in...



AED Class I recall

Welch Allyn's MRL division alerts customers June 14 that AED20 automated external defibrillators manufactured from April 2003 through October 2003 may fail to deliver appropriate therapy. Firm cites problems with an "electrical connection." The AED20 was the subject of another Class I recall in May 2005. Researchers highlighted concerns about AED recalls at Heart Rhythm Society Annual Meeting last month (1"The Gray Sheet" May 22, 2006, p. 12)...

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Xaira Launches With $1bn-Plus And End-To-End AI Strategy

ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025274

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel